Providence Wealth Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.08M | Buy |
44,086
+352
| +0.8% | +$9.21K | 0.64% | 46 |
|
|
2026
Q1 | $1.25M | Buy |
43,734
+2,977
| +7% | +$79.3K | 0.79% | 43 |
|
|
2025
Q4 | $1.02M | Sell |
40,757
-3,119
| -7% | -$78.7K | 0.64% | 46 |
|
|
2025
Q3 | $1.07M | Sell |
43,876
-324
| -0.7% | -$8K | 0.68% | 44 |
|
|
2025
Q2 | $1.07M | Buy |
44,200
+1,983
| +5% | +$46.2K | 0.74% | 45 |
|
|
2025
Q1 | $1.04M | Buy |
42,217
+874
| +2% | +$22.9K | 0.79% | 43 |
|
|
2024
Q4 | $1.12M | Sell |
41,343
-1,450
| -3% | -$39.3K | 0.85% | 41 |
|
|
2024
Q3 | $1.23M | Buy |
42,793
+91
| +0.2% | +$2.65K | 0.91% | 37 |
|
|
2024
Q2 | $1.22M | Buy |
42,702
+847
| +2% | +$23.3K | 0.97% | 36 |
|
|
2024
Q1 | $1.16M | Buy |
41,855
+32,690
| +357% | +$907K | 0.99% | 35 |
|
|
2023
Q4 | $1.46M | Sell |
9,165
-29,404
| -76% | -$889K | 1.32% | 22 |
|
|
2023
Q3 | $1.3M | Buy |
38,569
+391
| +1% | +$13.8K | 1.46% | 24 |
|
|
2023
Q2 | $1.39M | Sell |
38,178
-2,210
| -5% | -$86K | 1.54% | 23 |
|
|
2023
Q1 | $1.62M | Buy |
40,388
+188
| +0.5% | +$8.12K | 1.2% | 26 |
|
|
2022
Q4 | $2M | Buy |
40,200
+393
| +1% | +$18.8K | 1.48% | 24 |
|
|
2022
Q3 | $1.89M | Sell |
39,807
-1,191
| -3% | -$57.9K | 1.41% | 24 |
|
|
2022
Q2 | $2.14M | Buy |
40,998
+1,726
| +4% | +$88K | 1.54% | 17 |
|
|
2022
Q1 | $2.02M | Buy |
39,272
+158
| +0.4% | +$8.2K | 1.3% | 25 |
|
|
2021
Q4 | $2.16M | Sell |
39,114
-192
| -0.5% | -$9.51K | 1.36% | 19 |
|
|
2021
Q3 | $1.67M | Sell |
39,306
-1,098
| -3% | -$48.6K | 1.16% | 25 |
|
|
2021
Q2 | $1.6M | Buy |
40,404
+230
| +0.6% | +$8.94K | 1.09% | 29 |
|
|
2021
Q1 | $1.46M | Buy |
40,174
+1,145
| +3% | +$40.7K | 1.07% | 30 |
|
|
2020
Q4 | $1.43M | Sell |
39,029
-290
| -0.7% | -$10.6K | 1.19% | 26 |
|
|
2020
Q3 | $1.37M | Sell |
39,319
-14,263
| -27% | -$500K | 1.35% | 24 |
|
|
2020
Q2 | $1.66M | Sell |
53,582
-465
| -0.9% | -$15.8K | 1.7% | 19 |
|
|
2020
Q1 | $1.65M | Buy |
54,047
+164
| +0.3% | +$5.59K | 1.99% | 16 |
|
|
2019
Q4 | $1.99M | Sell |
53,883
-2,298
| -4% | -$81.9K | 1.83% | 14 |
|
|
2019
Q3 | $1.92M | Sell |
56,181
-411
| -0.7% | -$14.9K | 1.71% | 17 |
|
|
2019
Q2 | $2.35M | Sell |
56,592
-228
| -0.4% | -$9.05K | 2.19% | 12 |
|
|
2019
Q1 | $2.3M | Buy |
56,820
+732
| +1% | +$29.3K | 2.17% | 11 |
|
|
2018
Q4 | $2.29M | Sell |
56,088
-927
| -2% | -$38.5K | 2.54% | 9 |
|
|
2018
Q3 | $2.38M | Buy |
57,015
+345
| +0.6% | +$13.3K | 2.18% | 11 |
|
|
2018
Q2 | $1.95M | Buy |
56,670
+375
| +0.7% | +$12.8K | 1.9% | 13 |
|
|
2018
Q1 | $1.87M | Buy |
+56,295
| New | +$1.94M | 2.77% | 6 |
|
Other funds holding PFE
Providence Wealth Advisors's PFE Position: Q2 2026 in Review
Providence Wealth Advisors increased its Pfizer (PFE) stake by 0.8% in Q2 2026, buying an estimated $9.21K and bringing the position to 44,086 shares worth $1.08M. The position accounts for 0.64% of the portfolio, ranked #46.
Providence Wealth Advisors first reported a position in PFE in Q1 2018 and has held it in 34 quarters since. The position peaked at $2.38M in Q3 2018. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Providence Wealth Advisors held 44,086 shares of Pfizer worth $1.08M as of Q2 2026.
- Providence Wealth Advisors bought 352 Pfizer shares in Q2 2026, an estimated $9.21K.
- Pfizer made up 0.64% of Providence Wealth Advisors's portfolio in Q2 2026, its #46 holding.
- Providence Wealth Advisors first reported a position in Pfizer in Q1 2018 and has held it in 34 quarters since.
- Providence Wealth Advisors's Pfizer position peaked at $2.38M in Q3 2018.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Providence Wealth Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.